What is the prevalence of thyroid cancer in patients with hypothyroidism and vice versa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prevalence of Thyroid Cancer in Hypothyroidism and Vice Versa

The relationship between hypothyroidism and thyroid cancer is not straightforward—hypothyroidism itself does not appear to significantly increase thyroid cancer risk, while thyroid cancer represents only a tiny fraction (approximately 1.2% lifetime risk) of the general population, making co-occurrence relatively uncommon. 1

Thyroid Cancer Prevalence in Hypothyroid Patients

The evidence regarding hypothyroidism and thyroid cancer risk is limited and somewhat contradictory:

  • A large Danish nationwide cohort study found that hypothyroidism was NOT significantly associated with increased thyroid cancer risk, unlike other benign thyroid conditions such as hyperthyroidism, goiter, and adenomas which showed elevated standardized incidence ratios. 2

  • A Spanish hospital cohort using big data analysis found that patients with hypothyroidism had approximately twice the frequency of cancer overall (OR 2.09,95% CI 2.01-2.17) compared to non-hypothyroid subjects, though this association disappeared in patients over 60 years of age (OR 0.97). 3 However, this study examined all cancers, not specifically thyroid cancer, and the association may reflect surveillance bias or shared risk factors rather than causation.

  • An older Massachusetts General Hospital cohort study found no excess thyroid cancer mortality in hypothyroid women (SMR = 1.0,95% CI 0.7-1.4), suggesting hypothyroidism does not meaningfully increase thyroid cancer risk. 4

The key clinical implication: hypothyroidism alone should not trigger aggressive thyroid cancer screening beyond standard nodule evaluation protocols. 2

Hypothyroidism Prevalence in Thyroid Cancer Patients

The reverse relationship—how often thyroid cancer patients develop hypothyroidism—depends entirely on treatment:

  • Thyroid cancer itself does not inherently cause hypothyroidism before treatment, as most differentiated thyroid cancers (which represent nearly 95% of cases) arise in otherwise functioning thyroid tissue. 1, 5

  • Post-treatment hypothyroidism is essentially universal after total thyroidectomy, which is the standard treatment for most thyroid cancers with high-risk features (extrathyroidal extension, lymph node metastases, tumors >4 cm, distant metastases). 1

  • TSH suppression therapy is deliberately used in thyroid cancer management, maintaining TSH levels below 0.1 mU/L in high-risk patients and at the lower limit of normal in low-risk patients, requiring lifelong levothyroxine replacement. 1

Baseline Population Context

To understand these relationships, consider the baseline epidemiology:

  • Thyroid nodules are extremely common (approximately 5% palpable prevalence in those ≥50 years, 50% prevalence on ultrasound or autopsy), but are almost always benign. 1

  • Thyroid cancer lifetime risk is only 1.2% in the US population (0.83% for women, 0.33% for men), making it relatively uncommon despite increasing incidence rates. 1

  • The incidence of thyroid cancer has nearly tripled from 1975 to 2009 (from 4.9 to 14.3 per 100,000), but mortality has remained stable at approximately 0.5 deaths per 100,000, strongly suggesting an epidemic of overdiagnosis rather than true disease. 6, 7

  • Papillary thyroid carcinoma accounts for approximately 80% of all thyroid cancers, with 10-year survival rates of 93%. 1

Clinical Pitfalls to Avoid

  • Do not assume that hypothyroidism increases thyroid cancer risk—the evidence does not support routine intensified surveillance in hypothyroid patients beyond standard nodule evaluation criteria (nodules >1-1.5 cm or those with suspicious ultrasound features). 1, 2

  • Do not confuse Hashimoto's thyroiditis with simple hypothyroidism—while some studies suggest possible associations between autoimmune thyroiditis and papillary thyroid cancer, this is distinct from hypothyroidism as a general category. 5

  • Recognize that increased cancer detection in thyroid disease patients may reflect surveillance bias—patients with any thyroid condition receive more frequent imaging and evaluation, leading to detection of subclinical cancers that might never have caused harm. 6, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Benign Thyroid Diseases and Risk of Thyroid Cancer: A Nationwide Cohort Study.

The Journal of clinical endocrinology and metabolism, 2018

Guideline

Papillary Thyroid Cancer in Hashimoto's Thyroiditis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Is there really an increased incidence of thyroid cancer?

Current opinion in endocrinology, diabetes, and obesity, 2014

Research

Current thyroid cancer trends in the United States.

JAMA otolaryngology-- head & neck surgery, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.